Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sara Michell Tolaney, M.D.

Co-Author

This page shows the publications co-authored by Sara Tolaney and Nabihah Tayob.
Connection Strength

1.759
  1. The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2021 11 02; 113(11):1453-1459.
    View in: PubMed
    Score: 0.248
  2. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563.
    View in: PubMed
    Score: 0.246
  3. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110.
    View in: PubMed
    Score: 0.245
  4. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
    View in: PubMed
    Score: 0.242
  5. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
    View in: PubMed
    Score: 0.241
  6. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):983-991.
    View in: PubMed
    Score: 0.233
  7. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 Nov; 26(11):927-933.
    View in: PubMed
    Score: 0.062
  8. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103.
    View in: PubMed
    Score: 0.061
  9. Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.
    View in: PubMed
    Score: 0.061
  10. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.
    View in: PubMed
    Score: 0.060
  11. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.